[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356757-105":59,"doc-detail-356757-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","modeling-metastasis-and-predicting-drug-response-with-malignant-effusion-derived-organoids-a-systematic-review-and-quantitative-assessment","Modeling metastasis and predicting drug response with malignant effusion-derived organoids: a systematic review and quantitative assessment","","Malignant effusions offer a key window into metastatic biology, and malignant effusion-derived organoids (ME-PDTOs) are proposed to model metastasis and forecast drug response. This systematic review synthesizes evidence on ME-PDTO validity as a metastasis model and its concordance with clinical treatment outcomes. Studies over the past 15 years were selected under PRISMA 2020, extracting genetic, transcriptional, functional, and clinical correlations. Sixteen studies (87 ME-PDTOs from 84 patients) were included, showing retained driver mutations, EMT and stemness pathway enrichment, and functional migratory, invasive, and in vivo metastatic capacity.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/modeling-metastasis-and-predicting-drug-response-with-malignant-effusion-derived-organoids-a-systematic-review-and-quantitative-assessment/356757/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/modeling-metastasis-and-predicting-drug-response-with-malignant-effusion-derived-organoids-a-systematic-review-and-quantitative-assessment/356757.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What does the review assess about malignant effusion-derived organoids (ME-PDTOs)?","Question",{"text":113,"@type":114},"The review evaluates whether ME-PDTOs can model metastasis and how well they match clinical drug response outcomes.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were studies selected and analyzed in this systematic review?",{"text":118,"@type":114},"Studies from the past 15 years were identified and selected according to PRISMA 2020, with extraction of genetic, transcriptional, functional, and clinical correlation data. A descriptive study-level analysis was performed due to limitations in sample size and heterogeneity, and predictive performance was calculated with 95% confidence intervals.",{"name":120,"@type":111,"acceptedAnswer":121},"What overall findings relate ME-PDTOs to metastasis features and drug response?",{"text":122,"@type":114},"ME-PDTOs retained key driver mutations and showed EMT and stemness transcriptomic enrichment, along with migratory, invasive, and in vivo metastatic functions. In drug response evidence (mainly lung cancer), sensitivity and specificity suggested a promising correlative trend, although confidence intervals were wide in smaller studies.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356757,1791074144,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Peng et al. Journal of Translational Medicine (2026) 24:649  \n[https://doi.org/10.1186/s12967-026-08107-z](https://doi.org/10.1186/s12967-026-08107-z)  \nJournal of Translational Medicine  \nREVIEW Open Access  \nModeling metastasis and predicting drug response with malignant effusionderived organoids: a systematic review and quantitative assessment  \nJingyu Peng1,2,3, Shuting Tian1,2,3, Li Liu3,4 and Yifang Deng1,2,3*  \nAbstract  \nBackground Malignant effusions provide a critical window into metastatic biology. Malignant effusion-derived organoids (ME-PDTOs) hold promise for modeling metastasis and predicting drug response, but the evidence remains fragmented. This systematic review aims to synthesize current evidence on the validity of ME-PDTOs as metastasis models and their concordance with clinical drug responses.  \nMethods We systematically reviewed literature from the past 15 years in strict accordance with PRISMA 2020 guidelines for study identification and selection. Data on genetic, transcriptional, functional, and clinical correlation were extracted. Given sample size limitations and heterogeneity, a descriptive, study-level analysis was performed. Predictive performance (sensitivity, specificity) was calculated with 95% confidence intervals using multiple methods. Results Sixteen studies (87 ME-PDTOs from 84 patients) were included. ME-PDTOs retained key driver mutations and displayed transcriptomic enrichment of epithelial-mesenchymal transition and stemness pathways. Functionally, they demonstrated migratory, invasive, and in vivo metastatic capacity. For drug response, six studies provided 77 drug-patient pairs (predominantly lung cancer, 89 . 6%) . In the two largest lung cancer studies, ME-PDTO sensitivity for predicting clinical efficacy ranged from 0.82 to 0 . 90, and specificity from 0.80 to 1. 00, though confidence intervals were wide in smaller studies.  \nConclusion Current evidence suggests that ME-PDTOs can recapitulate key metastatic features and show a promising correlative trend with clinical drug responses in lung cancer. However, significant limitations exist: evidence is limited, heterogeneous, and subject to selection and measurement biases. Future standardized, prospective studies are needed to validate their clinical predictive utility and address translational challenges.  \nTrial registration registration number (PROSPERO) CRD420251107909 .  \nKeywords Patient-derived organoids, Malignant effusions, Tumor metastasis, Intratumoral heterogeneity, Personalized medicine  \n*Correspondence:  \nYifang Deng  \n[dengyifang_dyf@163.com](dengyifang_dyf@163.com)  \n1China State Institute of Pharmaceutical Industry, Shanghai 201203, China 2Shanghai Professional and Technical Service Center for Biological Material Draggability Evaluation, Shanghai 200437, China  \n3National Key Laboratory of Lead Druggability, Shanghai Institute of Pharmaceutical Industry, Shanghai 200437, China  \n4Shanghai Cell Wisdom Digital Technology Co., Ltd., Shanghai 200232, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this","cbCaigIEaNIJZV6X","https://ap.wps.com/l/cbCaigIEaNIJZV6X","pdf",1336464,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What does the review assess about malignant effusion-derived organoids (ME-PDTOs)?\",\"answer\":\"The review evaluates whether ME-PDTOs can model metastasis and how well they match clinical drug response outcomes.\"},{\"question\":\"How were studies selected and analyzed in this systematic review?\",\"answer\":\"Studies from the past 15 years were identified and selected according to PRISMA 2020, with extraction of genetic, transcriptional, functional, and clinical correlation data. A descriptive study-level analysis was performed due to limitations in sample size and heterogeneity, and predictive performance was calculated with 95% confidence intervals.\"},{\"question\":\"What overall findings relate ME-PDTOs to metastasis features and drug response?\",\"answer\":\"ME-PDTOs retained key driver mutations and showed EMT and stemness transcriptomic enrichment, along with migratory, invasive, and in vivo metastatic functions. In drug response evidence (mainly lung cancer), sensitivity and specificity suggested a promising correlative trend, although confidence intervals were wide in smaller studies.\"}]","Modeling metastasis and predicting drug response with malignant effusion-derived organoids: a systematic review and quantitative assessment | PDF",1790127147,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f76ff5425383f17394006e5de80e13d.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d56354ff42a25539b55237c0271a005f.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/346f025dcebc89ef062441d81b01fbd4.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69e14afc9ba11cc6477616c44e162501.webp",980,1306]